Incannex Healthcare
Update in progressIXHL (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company based in Sydney, Australia. It develops psychedelic medicines and other therapies for chronic diseases. Its programs include IHL-42X, an oral fixed-dose combo of dronabinol and acetazolamide in Phase 2/3 for obstructive sleep apnea; PSX-001, an oral synthetic psilocybin in Phase 2b for generalized anxiety disorder; and IHL-675A, a fixed-dose cannabidiol plus hydroxychloroquine sulfate for rheumatoid arthritis and related lung and inflammatory conditions.
Company score
- Sentiment
- 0.34
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.18
- Governance
- 0.16
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.09
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.22
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationAustralia
- CEOMr. Joel Bradley Latham
- Employees12
- Websitewww.incannex.com
Identifiers
- ISINUS45333F2083
- FIGIBBG0125CL1D2
- CIK0001873875